Pharma/fine chemicals roundup—11 February 2014
3:35 AM MST | February 11, 2014 | By DEEPTI RAMESH
Teva’s API business reports fall in sales
The active pharmaceutical ingredient (API) business of Teva Pharmaceutical Industries (Petaḥ Tiqwa, Israel) reports a 19.3% fall in sales in the fourth quarter of 2013, compared with the fourth quarter of 2012, to $163 million. For the full year 2013, the API business reports a 13% fall in sales, compared with 2012, to $692 million. Earnings figures for the API business were not disclosed. Teva has the largest API business in the world in terms of sales.
US FDA commissioner visits India to strengthen cooperation with Indian regulators
The US Food and Drug Administration (FDA) says that FDA commissioner Margaret Hamburg will be in India from 10-18 February, to further strengthen cooperation between the FDA and its Indian regulatory counterparts. This is Hamburg’s first official trip to India. During the trip, which will include visits to Delhi, Cochin, and Mumbai, Hamburg will meet with Indian policy and government leaders involved in the regulation of medical and food products exported to the United States. Currently, India is the second largest provider of finished drug products and the eighth largest exporter of food products to the United States, FDA says. “The FDA’s ongoing engagement with our regulatory counterparts in India is critical to our ability to effectively promote the health and safety of American and Indian consumers,” Hamburg says. “I look forward to enhancing our existing relationship and identifying additional opportunities for collaboration.”
The cooperation of United States and Indian food and drug officials is wide ranging, from sharing information on the conduct of clinical trials to jointly addressing product safety issues that may have an impact on both American and Indian consumers, FDA says. Hamburg will also meet with industry leaders in India to discuss the importance of maintaining high-quality standards in producing goods to ensure consumers have access to safe products.
SAFC reports rise in sales
SAFC Commercial, the custom-manufacturing and services business unit of Sigma-Aldrich, reports a 9% increase in sales in the fourth quarter of 2013 compared with the year-ago quarter, to $181 million. For the full year 2013, SAFC reports sales of $673 million, an increase of 7.3% compared with 2012. Earnings figures for the business have not been disclosed.
From 1 January 2013, Sigma-Aldrich aligned its organization into three market-focused business units: research, applied, and SAFC Commercial. SAFC Commercial serves customers in the life sciences and electronic markets.
“The SAFC Commercial business unit had a solid year and finished on a strong note with double-digit organic sales growth in the fourth quarter of 2013,” says Rakesh Sachdev, president and CEO of Sigma-Aldrich. “The life science products segment was a strong performer throughout the year, and the life science services segment saw a significant improvement in organic sales growth in 2013 as compared to 2012,” Sachdev says.
Ranbaxy’s API sales fall on lower demand
The active pharmaceutical ingredient (API) business of Ranbaxy Laboratories (Gurgaon, India) reports sales of 1.37 billion Indian rupees ($22 million) in the fourth quarter of 2013, compared with sales of Rs2.14 billion in the year-ago quarter. For the full year 2013, the API business reports sales of Rs6.92 billion, compared with sales of Rs7.30 billion in 2012. Sales in the API business were affected by lower demand, Ranbaxy says. Earnings figures for the API business were not disclosed.
Johnson Matthey appoints new group finance director
Johnson Matthey says that Den Jones will join the board of Johnson Matthey on 5 June 2014, succeeding Robert MacLeod as group finance director. Johnson Matthey recently announced that MacLeod will succeed Neil Carson as CEO when Carson steps down on 5 June. Jones has 13 years of senior and board level experience with energy company BG Group (Reading, UK).
Asahi Kasei opens pharmaceutical plant
Asahi Kasei says that its Asahi Kasei Pharma (Tokyo) subsidiary has opened a second manufacturing facility at its site at Miyoshi, Japan. The new facility will be used to manufacture Asahi Kasei Pharma’s flagship products: Teribone osteoporosis drug and Recomodulin anticoagulant. The plant involved an investment of ¥3.4 billion ($33 million).